Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9789046 | 0.81 | CA12 (0.31) | BRPF1 | |
| SCHEMBL30963678 | 0.75 | BRPF1 (0.44) | BRPF1HSD17B3BRD4PTPN1MEN1 | |
| SCHEMBL2731241 | 0.75 | BRPF1 (0.44) | BRPF1HSD17B3BRD4PTPN1MEN1 | |
| SCHEMBL14433005 | 0.65 | ALOX15 (0.34) | BRPF1GAAALOX15HSD17B10 | |
| SCHEMBL4476006 | 0.65 | BRPF1 (1.00) | BRPF1HSD17B3BRD4GAAKMT2A | |
| SCHEMBL30537994 | 0.65 | BRPF1 (1.00) | BRPF1HSD17B3BRD4GAAKMT2A | |
| SCHEMBL4158789 | 0.65 | BRPF1 (0.62) | BRPF1HSD17B3BRD4MEN1GAA | |
| SCHEMBL9375733 | 0.64 | BRPF1 (0.45) | BRPF1HSD17B3BRD4PTPN1MEN1 | |
| SCHEMBL4013751 | 0.62 | BRPF1 (0.50) | BRPF1HSD17B3BRD4MEN1GAA | |
| SCHEMBL30738818 | 0.62 | BRPF1 (0.50) | BRPF1HSD17B3BRD4MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560454-B2 | Condensed azepines as vasopressin agonists | VANTIA LIMITED (GB) | 2009-07-14 | — | — | US | disclosed |
| US-7560454-B2 | Condensed azepines as vasopressin agonists | VANTIA LIMITED (GB) | 2009-07-14 | — | — | US | disclosed |
| US-20080261951-A1 | Condensed azepines as vasopressin agonists | ASHWORTH DOREEN MARY | 2008-10-23 | — | — | US | disclosed |
| US-20080261951-A1 | Condensed azepines as vasopressin agonists | ASHWORTH DOREEN MARY | 2008-10-23 | — | — | US | disclosed |
| EP-1248784-B1 | CONDENSED AZEPINES AS VASOPRESSIN AGONISTS | FERRING BV (NL) | 2007-07-11 | — | — | EP | disclosed |
| US-7176195-B2 | Fused azepine derivatives and their use as antidiuretic agents | FERRING BV (NL) | 2007-02-13 | — | — | US | disclosed |
| US-7176195-B2 | Fused azepine derivatives and their use as antidiuretic agents | FERRING BV (NL) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261951-A1 | Condensed azepines as vasopressin agonists | AVPR2, AVPR1A, AVPR1B | BRPF1 708/4885HSD17B3 751/4885BRD4 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.